Biologics are transforming treatment for kids with spondyloarthritis — but gaps remain

Biologics are reshaping the treatment landscape for juvenile spondyloarthritis (SpA), with experts calling TNF and IL-17 inhibitors "game-changing" for young patients. The IL-17 inhibitor ixekizumab showed strong results in the phase III COSPIRIT-JIA trial, with 90% and 86% of biologic-naive and -experienced participants achieving treatment success at week 16 — potentially paving the way for an expanded pediatric indication. Meanwhile, secukinumab remains the only FDA-approved biologic for enthesitis-related arthritis (ERA) in children, leaving many patients relying on off-label therapies.

Experts emphasize that starting biologics early in juvenile SpA could prevent long-term complications like hip replacements and spinal damage, since axial disease can develop 5–10 years after an ERA diagnosis. However, the 2026 ACR guideline update notes that many recommendations carry only "conditional" status due to limited evidence, and no single biologic agent is officially preferred over another.

Key Takeaways:

• Up to 20% of SpA cases begin in childhood, sometimes as young as age 5
• Up to 40% of children with ERA may go on to develop juvenile ankylosing spondylitis
• IL-17 inhibitors should be avoided in patients with inflammatory bowel disease (e.g., Crohn's, ulcerative colitis)
• TNF inhibitors are generally recommended as the first biologic choice, absent contraindications

Why it matters: With juvenile SpA capable of causing lifelong joint damage, expanding safe and effective biologic options for children is critical. Early intervention may alter disease trajectories — but clinicians and families need better evidence and more approved therapies to make fully informed treatment decisions.